HER2阳性转移性乳腺癌-话题@MedSci

#HER2阳性转移性乳腺癌#

17篇内容 | 1623人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2130154, encodeId=a7992130154fb, content=中国医学科学院<a href='/topic/show?id=4804503e4d0' target=_blank style='color:#2F92EE;'>#徐兵河#</a>团队发现<a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a>加<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>可显著提高<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>的总生存期, objectTitle=STTT | 中国医学科学院徐兵河团队发现吡咯替尼加卡培他滨可显著提高HER2阳性转移性乳腺癌的总生存期, objectType=article, longId=763783, objectId=7163e63783ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/health-insurance-PK235DP.jpg, objectUrl=/article/show_article.do?id=7163e63783ea, replyNumber=0, likeNumber=154, createdTime=2023-05-05, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7163e63783ea, moduleTitle=STTT | 中国医学科学院徐兵河团队发现吡咯替尼加卡培他滨可显著提高HER2阳性转移性乳腺癌的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7163e63783ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643107, encodeId=c042164310e52, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌, objectType=article, longId=301648, objectId=93a0301648a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93a0301648a6, replyNumber=0, likeNumber=112, createdTime=2023-03-06, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93a0301648a6, moduleTitle=NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93a0301648a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643106, encodeId=5af216431065b, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=Front Oncol：吡咯替尼联合长春瑞滨治疗HER2阳性转移性乳腺癌的疗效:多中心回顾性研究, objectType=article, longId=219072, objectId=03b82190e28e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03b82190e28e, replyNumber=0, likeNumber=99, createdTime=2022-05-25, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03b82190e28e, moduleTitle=Front Oncol：吡咯替尼联合长春瑞滨治疗HER2阳性转移性乳腺癌的疗效:多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03b82190e28e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643104, encodeId=1f1e1643104e7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, objectType=article, longId=214659, objectId=4cc12146596f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cc12146596f, replyNumber=0, likeNumber=84, createdTime=2021-11-01, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cc12146596f, moduleTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cc12146596f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643105, encodeId=e7bb16431059f, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=ADC药物大展拳脚！突破性III期数据显示：Enhertu可降低HER2阳性转移性乳腺癌患者进展或死亡风险72%, objectType=article, longId=217554, objectId=e59521e554a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e59521e554a3, replyNumber=0, likeNumber=85, createdTime=2022-08-25, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e59521e554a3, moduleTitle=ADC药物大展拳脚！突破性III期数据显示：Enhertu可降低HER2阳性转移性乳腺癌患者进展或死亡风险72%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e59521e554a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643101, encodeId=024f164310115, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性, objectType=article, longId=199369, objectId=112e19936941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112e19936941, replyNumber=0, likeNumber=93, createdTime=2021-02-04, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112e19936941, moduleTitle=Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112e19936941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643103, encodeId=520d16431030f, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌, objectType=article, longId=204512, objectId=cc0e204512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc0e204512c6, replyNumber=0, likeNumber=108, createdTime=2021-01-04, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc0e204512c6, moduleTitle=CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc0e204512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643100, encodeId=49b01643100db, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, objectType=article, longId=192476, objectId=9a771924e693, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a771924e693, replyNumber=0, likeNumber=97, createdTime=2020-05-11, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a771924e693, moduleTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a771924e693)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643102, encodeId=9b2116431025c, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准, objectType=article, longId=200277, objectId=dacc2002e766, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dacc2002e766, replyNumber=0, likeNumber=125, createdTime=2021-07-07, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dacc2002e766, moduleTitle=NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dacc2002e766)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643099, encodeId=0ca116430995f, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, objectType=article, longId=184671, objectId=d1461846e154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1461846e154, replyNumber=0, likeNumber=91, createdTime=2020-11-17, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1461846e154, moduleTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1461846e154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643095, encodeId=1af016430951b, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）, objectType=article, longId=167604, objectId=9de016e60451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9de016e60451, replyNumber=0, likeNumber=140, createdTime=2019-07-30, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9de016e60451, moduleTitle=ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9de016e60451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643097, encodeId=1658164309e63, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=JCO：HER2阳性转移性乳腺癌研究进展, objectType=article, longId=178332, objectId=005e1e833230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=005e1e833230, replyNumber=0, likeNumber=107, createdTime=2020-04-21, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=005e1e833230, moduleTitle=JCO：HER2阳性转移性乳腺癌研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=005e1e833230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643098, encodeId=37911643098be, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , objectType=article, longId=184672, objectId=90f01846e265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90f01846e265, replyNumber=0, likeNumber=98, createdTime=2020-03-14, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90f01846e265, moduleTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90f01846e265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643096, encodeId=7c861643096ed, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=殷文瑾教授：复发/难治性HER2阳性转移性乳腺癌患者的新期待, objectType=article, longId=167882, objectId=cd6516e8827a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd6516e8827a, replyNumber=0, likeNumber=91, createdTime=2019-06-29, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd6516e8827a, moduleTitle=殷文瑾教授：复发/难治性HER2阳性转移性乳腺癌患者的新期待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd6516e8827a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643094, encodeId=d1db164309432, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果, objectType=article, longId=99073, objectId=0118990e3ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0118990e3ca, replyNumber=0, likeNumber=138, createdTime=2018-01-08, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0118990e3ca, moduleTitle=JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0118990e3ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643093, encodeId=fd421643093d7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期, objectType=article, longId=48932, objectId=982548932ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=982548932ef, replyNumber=0, likeNumber=115, createdTime=2016-03-02, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=982548932ef, moduleTitle=NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=982548932ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643092, encodeId=e8d51643092e5, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, objectTitle=HER2阳性转移性乳腺癌TKI治疗基于分子标志物的预后及疗效分析, objectType=article, longId=3780, objectId=8ee93e804e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ee93e804e, replyNumber=0, likeNumber=108, createdTime=2012-07-17, rootId=0, userName=lvliquan, userId=5d2523108579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ee93e804e, moduleTitle=HER2阳性转移性乳腺癌TKI治疗基于分子标志物的预后及疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ee93e804e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性转移性乳腺癌

2020-05-29

侠胆医心

中国医学科学院#徐兵河#团队发现#吡咯替尼#加#卡培他滨#可显著提高#HER2阳性转移性乳腺癌#的总生存期

STTT | 中国医学科学院徐兵河团队发现吡咯替尼加卡培他滨可显著提高HER2阳性转移性乳腺癌的总生存期

2023-05-05发表于上海

lvliquan

#HER2阳性转移性乳腺癌#

NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌

2023-03-06

lvliquan

#HER2阳性转移性乳腺癌#

Front Oncol：吡咯替尼联合长春瑞滨治疗HER2阳性转移性乳腺癌的疗效:多中心回顾性研究

2022-05-25

智慧医人

#HER2阳性转移性乳腺癌#

Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌

2021-11-01

lvliquan

#HER2阳性转移性乳腺癌#

ADC药物大展拳脚！突破性III期数据显示：Enhertu可降低HER2阳性转移性乳腺癌患者进展或死亡风险72%

2022-08-25

lvliquan

#HER2阳性转移性乳腺癌#

Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性

2021-02-04

lvliquan

#HER2阳性转移性乳腺癌#

CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌

2021-01-04

lvliquan

#HER2阳性转移性乳腺癌#

FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌

2020-05-11

lvliquan

#HER2阳性转移性乳腺癌#

NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准

2021-07-07

lvliquan

#HER2阳性转移性乳腺癌#

NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗

2020-11-17

lvliquan

#HER2阳性转移性乳腺癌#

ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）

2019-07-30

lvliquan

#HER2阳性转移性乳腺癌#

JCO：HER2阳性转移性乳腺癌研究进展

2020-04-21

lvliquan

#HER2阳性转移性乳腺癌#

阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 

2020-03-14

lvliquan

#HER2阳性转移性乳腺癌#

殷文瑾教授：复发/难治性HER2阳性转移性乳腺癌患者的新期待

2019-06-29

lvliquan

#HER2阳性转移性乳腺癌#

JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果

2018-01-08

hb2008ye

#HER2阳性转移性乳腺癌#

NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期

2016-03-02

lvliquan

#HER2阳性转移性乳腺癌#

HER2阳性转移性乳腺癌TKI治疗基于分子标志物的预后及疗效分析

2012-07-17